Imricor Medical Systems (IMR) EGM 2024 summary
Event summary combining transcript, slides, and related documents.
EGM 2024 summary
23 Jan, 2026Opening remarks and agenda
Meeting opened with a welcome and instructions for voting and Q&A participation.
Quorum confirmed, meeting declared open and authorized to transact business.
Notice of meeting, proxy statement, and explanatory memorandum made available to all stakeholders.
Specific resolutions to be voted on
Ratification and approval of prior issue of 49,514,682 CDIs at AUD 0.52 per CDI under tranche one of the placement.
Approval for issue of up to 17,550,154 CDIs at AUD 0.52 per CDI under tranche two of the placement.
Approval for issue of up to 242,857 shares at $0.35 per share to accredited US investors under tranche two.
Board and executive committee updates
Introduction of four directors, CFO, and Company Secretary present at the meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Imricor Medical Systems
- Director elections, incentive plans, and auditor ratification passed with strong support; results pending.IMR
AGM 20268 May 2026 - A$60m placement funds global scale-up of MRI-guided cardiac ablation platform and clinical expansion.IMR
Investor presentation4 May 2026 - Major U.S. regulatory wins and clinical expansion drive commercial momentum, with strong funding position.IMR
Q1 2026 TU27 Apr 2026 - Regulatory wins, clinical milestones, and a $44M raise set stage for global expansion.IMR
H2 20259 Apr 2026 - World-first MRI-guided ablations and robust cash reserves drive global expansion.IMR
Q4 2025 TU27 Jan 2026 - Revenue up 105% and $35m AUD raised, but going concern risk persists.IMR
H1 202423 Jan 2026 - MRI-guided ablation is set for rapid adoption, backed by strong clinical results and global expansion.IMR
NWR Virtual Healthcare Conference26 Dec 2025 - Revenue up 56% with new approvals, but net loss and going concern risk remain.IMR
H2 202418 Dec 2025 - Revenue fell 52% and net loss widened, but a $44.1m equity raise strengthened liquidity.IMR
H1 202524 Nov 2025